# Parenteral anticoagulants in heart disease: Current stat

Thrombosis and Haemostasis
109, 769-786
DOI: 10.1160/th12-06-0403

Citation Report

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Vitamin K antagonists in heart disease: Current status and perspectives (Section III). Thrombosis and Haemostasis, 2013, 110, 1087-1107. | 1.8 | 347 |
| 2 | Non-Vitamin K Antagonist Oral Anticoagulants and the Treatment of Venous Thromboembolism in Cancer Patients: A Semi Systematic Review and Meta-Analysis of Safety and Efficacy Outcomes. PLoS ONE, 2014, 9, e114445. | 1.1 | 54 |
| 3 | Eficacia y seguridad del tratamiento anticoagulante oral con antagonistas de vitamina K en pacientes con prÃ³tesis valvulares cardÃacas. Revista Chilena De CardiologÃa, 2014, 33, 27-32. | 0.0 | 2 |
| 4 | Edoxaban: a new oral direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders. Clinical Investigation, 2014, 4, 619-639. | 0.0 | 2 |
| 5 | Contemporary anticoagulation therapy in patients undergoing percutaneous intervention. Expert Review of Cardiovascular Therapy, 2014, 12, 451-461. | 0.6 | 1 |
| 6 | Dabigatran etexilate for venous thromboembolism: a safety evaluation. Expert Opinion on Drug Safety, 2014, 13, 639-647. | 1.0 | 4 |
| 7 | Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays. Thrombosis Journal, 2014, 12, 24. | 0.9 | 45 |
| 8 | Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thrombosis and Haemostasis, 2014, 112, 781-782. | 1.8 | 142 |
| 9 | New Biomarkers and Risk Stratification in Atrial Fibrillation. Circulation, 2014, 130, 1837-1839. | 1.6 | 11 |
| 10 | Antithrombotic and Anticoagulant Therapy for Atrial Fibrillation. Cardiology Clinics, 2014, 32, 585-599. | 0.9 | 7 |
| 11 | The Reply. American Journal of Medicine, 2014, 127, e21. | 0.6 | 0 |
| 12 | One Weapon, Two Blows in the War Against the Thrombus. Journal of the American College of Cardiology, 2014, 63, 2699-2701. | 1.2 | 2 |
| 13 | Which risk score best predicts perioperative outcomes in nonvalvular atrial fibrillation patients undergoing noncardiac surgery?. American Heart Journal, 2014, 168, 60-67.e5. | 1.2 | 21 |
| 14 | Atrial Fibrillation and Heart Failure: A Bad Combination. American Journal of Cardiology, 2014, 113, 1196-1197. | 0.7 | 9 |
| 15 | Comparing the â€˜Newâ€™ R2CHADS2 With the â€˜Oldâ€™ CHA2DS2-VASc Scores for Predicting Thromboembolism in Patients Undergoing Atrial Fibrillation Ablation: New Does Not Mean Better. Canadian Journal of Cardiology, 2014, 30, 385-387. | 0.8 | 1 |
| 16 | MY APPROACH to the use of NOACs for stroke prevention in patients with atrial fibrillation*. Trends in Cardiovascular Medicine, 2014, 24, 265-266. | 2.3 | 2 |
| 17 | Atrial Fibrillation During Sepsis. Chest, 2014, 146, 1138-1140. | 0.4 | 2 |
| 18 | Assessing Bleeding Risk With the <scp>HASâ€BLED</scp> Score: Balancing Simplicity, Practicality, and Predictive Value in Bleedingâ€Risk Assessment. Clinical Cardiology, 2015, 38, 562-564. | 0.7 | 14 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | The <scp>HASâ€BLED</scp> Score for Predicting Major Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: A Systematic Review and Metaâ€analysis. Clinical Cardiology, 2015, 38, 555-561. | 0.7 | 141 |
| 20 | Effect of Active Smoking on Comparative Efficacy of Antithrombotic Therapy in Patients With Atrial Fibrillation. Chest, 2015, 148, 491-498. | 0.4 | 9 |
| 21 | Bivalirudin for acute coronary syndromes: premises, promises and doubts. Thrombosis and Haemostasis, 2015, 113, 698-707. | 1.8 | 14 |
| 22 | Time Trends of Aspirin and Warfarin Use on Stroke and Bleeding Events in Chinese Patients With New-Onset Atrial Fibrillation. Chest, 2015, 148, 62-72. | 0.4 | 40 |
| 23 | Stroke prevention in atrial fibrillation: Where are we now?. Indian Heart Journal, 2015, 67, S1-S3. | 0.2 | 1 |
| 24 | Association Between Usual Vitamin K Intake and Anticoagulation in Patients Under Warfarin Therapy. Clinical Nutrition Research, 2015, 4, 235. | 0.5 | 9 |
| 25 | The search for optimal anticoagulation therapy in ACS: The gap between clinical trials and current clinical guidelines. Thrombosis and Haemostasis, 2015, 114, 872-874. | 1.8 | 0 |
| 26 | Comparison of Atrial Fibrillation Guidelines. Journal of General Internal Medicine, 2015, 30, 1404-1404. | 1.3 | 0 |
| 27 | Stroke Prevention in Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2015, 313, 1950. | 3.8 | 258 |
| 28 | Comparison of non-vitamin K antagonist oral anticoagulants and warfarin on clinical outcomes in atrial fibrillation patients with renal dysfunction. Europace, 2015, 17, ii69-ii75. | 0.7 | 21 |
| 29 | Selection of Warfarin or One of the New Oral Antithrombotic Agents for Long-Term Prevention of Stroke among Persons with Atrial Fibrillation. Current Treatment Options in Neurology, 2015, 17, 331. | 0.7 | 1 |
| 30 | Fondaparinux in atrial fibrillation â€“ old dog, new tricks?. Archives of Cardiovascular Diseases, 2015, 108, 85-87. | 0.7 | 1 |
| 32 | Quality of Anticoagulation Control in Preventing Adverse Events in Patients With Heart Failure in Sinus Rhythm. Circulation: Heart Failure, 2015, 8, 504-509. | 1.6 | 21 |
| 33 | Non-Biological Complex Drugs. AAPS Advances in the Pharmaceutical Sciences Series, 2015, , . | 0.2 | 17 |
| 34 | Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace, 2015, 17, 1169-1196. | 0.7 | 138 |
| 35 | Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. European Heart Journal, 2015, 36, ehv304. | 1.0 | 175 |
| 36 | Low Molecular Weight Heparins, Biological Drugs close to Non-Biological Complex Drugs. AAPS Advances in the Pharmaceutical Sciences Series, 2015, , 291-331. | 0.2 | 0 |
| 37 | Switching from a vitamin K antagonist to a NOAC. Lancet Haematology,the, 2015, 2, e132-e133. | 2.2 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 38 | Intracranial Hemorrhage and Subsequent Ischemic Stroke in Patients With Atrial Fibrillation. Chest, 2015, 147, 1651-1658. | 0.4 | 43 |
| 39 | Optimizing Atrial Fibrillation Management. Chest, 2015, 148, 859-864. | 0.4 | 43 |
| 40 | Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis. Clinical Research in Cardiology, 2015, 104, 418-429. | 1.5 | 87 |
| 41 | Assessing Eligibility for Anticoagulation After Diagnosis of Atrial Fibrillationâ€"Reply. JAMA - Journal of the American Medical Association, 2015, 314, 949. | 3.8 | 1 |
| 42 | Stroke Risk Perception in Atrial Fibrillation Patients is not Associated with Clinical Stroke Risk. Journal of Stroke and Cerebrovascular Diseases, 2015, 24, 2527-2532. | 0.7 | 3 |
| 43 | Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. European Heart Journal: Acute Cardiovascular Care, 2015, 4, 386-386. | 0.4 | 46 |
| 44 | Edoxaban in venous thromboembolism and stroke prevention: an appraisal. Vascular Health and Risk Management, 2016, 12, 45. | 1.0 | 4 |
| 45 | Oral anticoagulants in coronary heart disease (Section IV) Position paper of the ESC Working Group on Thrombosis â€“ Task Force on Anticoagulants in Heart Disease. Thrombosis and Haemostasis, 2016, 115, 685-711. | 1.8 | 24 |
| 46 | New Approaches to the Role of Thrombin in Acute Coronary Syndromes: Quo Vadis Bivalirudin, a Direct Thrombin Inhibitor?. Molecules, 2016, 21, 284. | 1.7 | 2 |
| 47 | Cost-Effectiveness of Apixaban versus Warfarin in Chinese Patients with Non-Valvular Atrial Fibrillation: A Real-Life and Modelling Analyses. PLoS ONE, 2016, 11, e0157129. | 1.1 | 11 |
| 48 | Heparin monitoring: clinical outcome and practical approach. Annales De Biologie Clinique, 2016, 74, 637-652. | 0.2 | 4 |
| 49 | Stroke prevention in atrial fibrillation and â€˜real worldâ€™ adherence to guidelines in the Balkan Region: The BALKAN-AF Survey. Scientific Reports, 2016, 6, 20432. | 1.6 | 40 |
| 50 | Major Bleeding in Patients with Non-Valvular Atrial Fibrillation: Impact of Time in Therapeutic Range on Contemporary Bleeding Risk Scores. Scientific Reports, 2016, 6, 24376. | 1.6 | 49 |
| 51 | Comparison of hospital length of stay and hospitalization costs among patients with non-valvular atrial fibrillation treated with apixaban or warfarin: An early view. Journal of Medical Economics, 2016, 19, 769-776. | 1.0 | 13 |
| 52 | Degree of Anticoagulation Control in Patients With Atrial Fibrillation in Spain: Need to Minimize Biases and Contextualize Results. Response by Anguita SÃ¡nchez et al.. Revista Espanola De Cardiologia (English Ed ), 2016, 69, 356. | 0.4 | 0 |
| 53 | Grado de control de la anticoagulaciÃ³n en pacientes con fibrilaciÃ³n auricular en EspaÃ±a: necesidad de minimizar sesgos y contextualizar resultados. Respuesta de Anguita SÃ¡nchez et al. Revista Espanola De Cardiologia, 2016, 69, 356. | 0.6 | 1 |
| 54 | Outcomes in a Warfarin-Treated Population With Atrial Fibrillation. JAMA Cardiology, 2016, 1, 172. | 3.0 | 119 |
| 55 | The left atrial appendage: from embryology to prevention of thromboembolism. European Heart Journal, 2017, 38, ehw159. | 1.0 | 53 |

| # | Article | IF | Citations |
|---|---|---|---|
| 56 | Major bleeding risk among nonâ€valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a â€œrealâ€worldâ€•observational study in the United States. International Journal of Clinical Practice, 2016, 70, 752-763. | 0.8 | 100 |
| 57 | Patient knowledge of anticoagulant treatment does not correlate with treatment quality. Public Health, 2016, 141, 17-22. | 1.4 | 5 |
| 58 | The Reality of â€œReal-Worldâ€•Data. Journal of the American College of Cardiology, 2016, 68, 1402-1403. | 1.2 | 4 |
| 59 | Effectiveness and safety of vitamin K-antagonists in an anticoagulant clinic. Thrombosis Research, 2016, 147, 122-123. | 0.8 | 0 |
| 60 | European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). Europace, 2017, 19, euw242. | 0.7 | 67 |
| 61 | Adherence to antithrombotic therapy guidelines improves mortality among elderly patients with atrial fibrillation: insights from the REPOSI study. Clinical Research in Cardiology, 2016, 105, 912-920. | 1.5 | 63 |
| 62 | Chronic Kidney Disease, Time in Therapeutic Range and Adverse Clinical Outcomes in Anticoagulated Patients with Non-valvular Atrial Fibrillation: Observations from the SPORTIF Trials. EBioMedicine, 2016, 8, 309-316. | 2.7 | 31 |
| 63 | Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort. Europace, 2016, 18, 1308-1318. | 0.7 | 54 |
| 64 | Atrial Flutter and Fibrillation in the Emergency Setting. , 2016, , 61-87. | | 0 |
| 65 | Individualized approaches to thromboprophylaxis in atrial fibrillation. American Heart Journal, 2016, 173, 143-158. | 1.2 | 12 |
| 66 | Emerging Tools for Stroke Prevention in Atrial Fibrillation. EBioMedicine, 2016, 4, 26-39. | 2.7 | 15 |
| 68 | From clinical trials to real-world clinical practice: observations on the direct oral anticoagulants. Lancet Haematology,the, 2016, 3, e2-e3. | 2.2 | 2 |
| 69 | Point-of-Care Tests for Severe Hemorrhage. , 2016, , . | | 8 |
| 72 | Assessment of the Effects of Antithrombotic Drugs. , 2016, , 173-192. | | 0 |
| 73 | Polypharmacy and major adverse events in atrial fibrillation: observations from the AFFIRM trial. Clinical Research in Cardiology, 2016, 105, 412-420. | 1.5 | 78 |
| 74 | Preventing Thrombosis to Improve Outcomes in Heart Failure Patients. Progress in Cardiovascular Diseases, 2016, 58, 386-392. | 1.6 | 6 |
| 76 | Synergic impact of oral anticoagulation control and renal function in determining major adverse events in atrial fibrillation patients undergoing percutaneous coronary intervention: insights from the AFCAS registry. Clinical Research in Cardiology, 2017, 106, 420-427. | 1.5 | 4 |
| 77 | Integrating genotypes in the SAMe-TT 2 R 2 score for the prediction of anticoagulation control in Chinese patients with atrial fibrillation on warfarin. International Journal of Cardiology, 2017, 241, 358-363. | 0.8 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 78 | Efficacy and safety of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation. Open Heart, 2017, 4, e000682. | 0.9 | 27 |
| 79 | Importance of time in therapeutic range on bleeding risk prediction using clinical risk scores in patients with atrial fibrillation. Scientific Reports, 2017, 7, 12066. | 1.6 | 16 |
| 80 | The Patterns of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Use in Patients with Atrial Fibrillation in Seven Balkan Countries: a Report from the BALKAN-AF Survey. Advances in Therapy, 2017, 34, 2043-2057. | 1.3 | 17 |
| 81 | Relationship between atrial fibrillation and cognitive decline in individuals aged 80 and older. European Journal of Internal Medicine, 2017, 46, 6-10. | 1.0 | 16 |
| 82 | Personalized Anticoagulation. Circulation: Cardiovascular Genetics, 2017, 10, . | 5.1 | 8 |
| 83 | Antithrombotic treatment for ischaemic stroke. British Journal of Neuroscience Nursing, 2017, 13, S26-S34. | 0.1 | 0 |
| 84 | The role of oral anticoagulant therapy in patients with acute coronary syndrome. Therapeutic Advances in Hematology, 2017, 8, 353-366. | 1.1 | 21 |
| 85 | European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). European Journal of Preventive Cardiology, 2017, 24, 4-40. | 0.8 | 83 |
| 86 | Advances in anticoagulation management of patients undergoing cardioversion of nonvalvular atrial fibrillation. Hamostaseologie, 2017, 37, 277-285. | 0.9 | 2 |
| 87 | Antithrombotic treatment for ischaemic stroke. NursePrescribing, 2017, 15, 345-354. | 0.1 | 0 |
| 88 | Control of IBMIR Induced by Fresh and Cryopreserved Hepatocytes by Low Molecular Weight Dextran Sulfate versus Heparin. Cell Transplantation, 2017, 26, 71-81. | 1.2 | 11 |
| 89 | TRATAMIENTO ANTICOAGULANTE ORAL CON Ã‰NFASIS EN SUS INDICACIONES EN CARDIOLOGÃA. Revista MÃ©dica ClÃnica Las Condes, 2018, 29, 76-86. | 0.2 | 0 |
| 90 | Comparing Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) to Different Coumadins: The Win-Win Scenarios. Thrombosis and Haemostasis, 2018, 118, 803-805. | 1.8 | 7 |
| 91 | Optimizing Vitamin K Antagonist Treatment in Patients with Mechanical Heart Valve Prosthesis. Thrombosis and Haemostasis, 2018, 118, 806-807. | 1.8 | 1 |
| 93 | Optimal nonvitamin K antagonist oral anticoagulant therapy in a warfarin-sensitive patient after left atrial appendage closure. Medicine (United States), 2018, 97, e0683. | 0.4 | 3 |
| 95 | Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction. Nature Reviews Nephrology, 2018, 14, 337-351. | 4.1 | 89 |
| 96 | The Influence of CYP2C9 and VKORC1 Gene Polymorphisms on the Response to Warfarin in Egyptians. Indian Journal of Hematology and Blood Transfusion, 2018, 34, 328-336. | 0.3 | 3 |
| 97 | First Evidence: TRAP-Induced Platelet Aggregation Is Reduced in Patients Receiving Xabans. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 914-919. | 0.7 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 98 | Surgical embolectomy for acute massive pulmonary embolism: state of the art. Journal of Thoracic Disease, 2018, 10, 5154-5161. | 0.6 | 26 |
| 99 | Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients. Stroke, 2018, 49, 2933-2944. | 1.0 | 246 |
| 100 | Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban. PLoS ONE, 2018, 13, e0205989. | 1.1 | 47 |
| 101 | Oral anticoagulation and comorbidities; too many details for clinical practice?. International Journal of Cardiology, 2018, 264, 93-94. | 0.8 | 1 |
| 102 | Treatment and persistence with oral anticoagulants among newly diagnosed patients with non-valvular atrial fibrillation: a retrospective observational study in a US commercially insured and Medicare Advantage population. BMJ Open, 2018, 8, e020676. | 0.8 | 14 |
| 104 | Bridging anticoagulation therapy. Cor Et Vasa, 2018, 60, e400-e406. | 0.1 | 2 |
| 105 | Antithrombotic Therapy After Percutaneous Coronary Intervention in Atrial Fibrillation: The Triple Trouble. Drugs, 2018, 78, 1309-1319. | 4.9 | 1 |
| 106 | Clinical usefulness of the SAMe-TT2R2 score: A systematic review and simulation meta-analysis. PLoS ONE, 2018, 13, e0194208. | 1.1 | 12 |
| 107 | Poor warfarin anticoagulation in long-term thromboprophylaxis: a survey in a southern Croatian county. Croatian Medical Journal, 2019, 60, 2-11. | 0.2 | 3 |
| 108 | Therapeutic effect of vitamin K1 combined with meropenem on the treatment of pertussis syndrome. Experimental and Therapeutic Medicine, 2019, 18, 642-646. | 0.8 | 2 |
| 109 | Determinants of the Quality of Warfarin Control after Venous Thromboembolism and Validation of the SAMe-TT2-R2 Score: An Analysis of Hokusai-VTE. Thrombosis and Haemostasis, 2019, 119, 675-684. | 1.8 | 9 |
| 110 | Murcia atrial fibrillation project II: protocol for a prospective observational study in patients with atrial fibrillation. BMJ Open, 2019, 9, e033712. | 0.8 | 3 |
| 111 | Prognostic value of the model for end-stage liver disease excluding INR score (MELD-XI) in patients with adult congenital heart disease. PLoS ONE, 2019, 14, e0225403. | 1.1 | 13 |
| 112 | Increasing Time in Therapeutic Range of Tacrolimus in the First Year Predicts Better Outcomes in Living-Donor Kidney Transplantation. Frontiers in Immunology, 2019, 10, 2912. | 2.2 | 16 |
| 113 | The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section Vâ€"Special Situations. Thrombosis and Haemostasis, 2019, 119, 014-038. | 1.8 | 28 |
| 114 | Predictors for INR-control in a well-managed warfarin treatment setting. Journal of Thrombosis and Thrombolysis, 2019, 47, 227-232. | 1.0 | 10 |
| 115 | Is the time in therapeutic range on coumarins predicted by previous time in therapeutic range?. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 604-609. | 1.0 | 3 |
| 116 | Specialized Management of Oral Anticoagulation Therapy Improves Outcome in Patients with Chronic Renal Insufficiency. Journal of Clinical Medicine, 2020, 9, 645. | 1.0 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 117 | Electronic monitoring of adherence to onceâ€daily and twiceâ€daily direct oral anticoagulants in patients with atrial fibrillation: Baseline data from the SMAAPâ€AF trial. Journal of Arrhythmia, 2021, 37, 616-625. | 0.5 | 3 |
| 118 | Antithrombotic treatment in primary percutaneous coronary intervention. Expert Review of Cardiovascular Therapy, 2021, 19, 313-324. | 0.6 | 2 |
| 119 | Efficacy and Safety of the Fixed-Dose Versus Variable-Dose of 4-PCC for Vitamin K Antagonist Reversal: A Comprehensive Systematic Review and Meta-Analysis. Cardiovascular Drugs and Therapy, 2022, 36, 533-546. | 1.3 | 8 |
| 120 | Antithrombotic therapy in the elderly and senile age: the consensus opinion of experts of the Russian Association of Gerontologists and Geriatricians and the National Society of Preventive Cardiology. Cardiovascular Therapy and Prevention (Russian Federation), 2021, 20, 2847. | 0.4 | 3 |
| 121 | Thrombosis Prevention and Anticoagulation Management in the Pediatric Patient with Congenital Heart Disease. Cardiology and Therapy, 2021, 10, 325-348. | 1.1 | 6 |
| 122 | Heart failure and atrial fibrillation: new concepts in pathophysiology, management, and future directions. Heart Failure Reviews, 2022, 27, 1201-1210. | 1.7 | 18 |
| 124 | Publisherâ€™s note. European Heart Journal, 2015, 36, 2880-5. | 1.0 | 25 |
| 125 | Use of the SAMe-TT2R2 Score to Predict Good Anticoagulation Control with Warfarin in Chinese Patients with Atrial Fibrillation: Relationship to Ischemic Stroke Incidence. PLoS ONE, 2016, 11, e0150674. | 1.1 | 41 |
| 126 | The Potential Role of Edoxaban in Stroke Prevention Guidelines. Arrhythmia and Electrophysiology Review, 2014, 3, 40-43. | 1.3 | 2 |
| 127 | Comparing the ORBIT and HAS-BLED bleeding risk scores in anticoagulated atrial fibrillation patients: a systematic review and meta-analysis. Oncotarget, 2017, 8, 109703-109711. | 0.8 | 24 |
| 129 | Triple antithrombotic therapy in atrial fibrillation patients with acute coronary syndromes or undergoing percutaneous coronary intervention or transcatheter aortic valve replacement. EuroIntervention, 2015, 10, 1015-1021. | 1.4 | 21 |
| 130 | Post myocardial infarction and atrial fibrillation: Thromboprophylaxis and risk stratification using the CHA2DS2-VASc score. Cardiology Journal, 2014, 21, 451-453. | 0.5 | 7 |
| 131 | Stability of vitamin K antagonist anticoagulation after COVIDâ€19 diagnosis. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12597. | 1.0 | 3 |
| 132 | Efficacy and Safety of Direct Oral Anticoagulants in Patients with Diabetes and Nonvalvular Atrial Fibrillation: Meta-Analysis of Observational Studies. Cardiovascular Therapeutics, 2021, 2021, 1-14. | 1.1 | 4 |
| 133 | Empirical anticoagulation for patients in sinus rhythm at high risk of ischaemic stroke: A review of current literature. World Journal of Cardiology, 2017, 9, 422. | 0.5 | 1 |
| 136 | Predictors of Oral Anticoagulants Utilization in Patients with Atrial Fibrillation. Journal of Health and Allied Sciences, 2020, 10, 40-48. | 0.0 | 0 |
| 137 | Association between body mass index and the risk of bleeding in elderly patients with non-valvular atrial fibrillation taking dabigatran: a cohort study. Journal of Geriatric Cardiology, 2020, 17, 193-201. | 0.2 | 2 |
| 138 | Incremental Value of Genotype Bins over the HAS-BLED Score for the Prediction of Bleeding Risk in Warfarin-Treated Patients with Atrial Fibrillation. Cardiology Research and Practice, 2021, 2021, 1-8. | 0.5 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 139 | The Effect of Serum Magnesium Level on Stable Anticoagulation in Patients Using Warfarin for Various Cardiac Indications. Biological Trace Element Research, 2022, 200, 4297-4302. | 1.9 | 1 |
| 140 | Vitamin K-dependent anticoagulant use and level of anticoagulation control in sub-Saharan Africa: protocol for a retrospective cohort study. BMJ Open, 2022, 12, e057166. | 0.8 | 1 |
| 141 | Efficacy and Safety Profile of Novel Oral Anticoagulants in the Treatment of Left Atrial Thrombosis: A Systematic Review and Meta-Analysis. Current Therapeutic Research, 2022, 96, 100670. | 0.5 | 1 |
| 142 | Time trends in adherence to guideline recommendations for anticoagulation therapy in patients with atrial fibrillation and myocardial infarction. Open Heart, 2022, 9, e001934. | 0.9 | 2 |
| 148 | Incidence of nonvalvular atrial fibrillation and oral anticoagulant prescribing in England, 2009 to 2019: A cohort study. PLoS Medicine, 2022, 19, e1004003. | 3.9 | 10 |
| 149 | A Factor XIa Inhibitor Engineered from Banded Krait Venom Toxin: Efficacy and Safety in Rodent Models of Arterial and Venous Thrombosis. Biomedicines, 2022, 10, 1679. | 1.4 | 0 |
| 150 | Antithrombotic treatment switching in elderly patients with atrial fibrillation and the risk of thromboembolism, bleeding, and cardiac death. Research and Practice in Thrombosis and Haemostasis, 2022, 6, . | 1.0 | 0 |
| 151 | Efficacy and Safety of NOACs Compared With VKAs for Patients With Atrial Fibrillation After Transcatheter Aortic Valve Implantation: A System Review and Meta-Analysis. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962211451. | 0.7 | 0 |
| 152 | Clinical Decision Pathway for the Use of Fondaparinux in the Management of Acute Coronary Syndrome (ACS) in Hospitals with and Without Catheter Laboratories: An Expert Opinion from India. Cardiology and Therapy, 0, , . | 1.1 | 0 |
| 153 | Quality of anticoagulant control and patient experience associated with long-term warfarin in Canadian patients with non-valvular atrial fibrillation: A multicentre, prospective study. PLoS ONE, 2023, 18, e0284425. | 1.1 | 0 |
| 154 | Heparine und andere parenterale Antikoagulanzien. Springer Reference Medizin, 2023, , 1-13. | 0.0 | 0 |